Efavirenz concentrations in CSF exceed IC50 for wild-type HIV

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 2, 2011, Pages 354-357

  Best, Brookie M ^a,b   Koopmans, Peter P ^c   Letendre, Scott L ^d   Capparelli, Edmund V ^a,b   Rossi, Steven S ^b   Clifford, David B ^e   Collier, Ann C ^f   Gelman, Benjamin B ^g   Mbeo, Gilbert ^h   McCutchan, J Allen ^d   Simpson, David M ⁱ   Haubrich, Richard ^d   Ellis, Ronald ^d   Grant, Igor ^d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e WASHINGTON UNIVERSITY   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

CNS; Non nucleoside reverse transcriptase inhibitors; Pharmacology

Indexed keywords

EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; TENOFOVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PENETRATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MULTICENTER STUDY; NEUROLOGIC DISEASE;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HIV INFECTIONS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; RANDOM ALLOCATION; VIRAL LOAD;

EID: 78651456899     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq434     Document Type: Article

References (9)

1. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24: 1243-50.
2. Reddy YS, Kashuba A, Gerber J, et al. Roundtable report: importance of antiretroviral drug concentrations in sanctuary sites and viral reservoirs. AIDS Res Hum Retroviruses 2003; 19: 167-76.
3. van Praag RM, van Weert EC, van Heeswijk RP, et al. Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy. Antimicrob Agents Chemother 2002; 46: 896-9.
4. Tashima KT, Caliendo AM, Ahmad M, et al. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J Infect Dis 1999; 180: 862-4.
5. Antinori A, Perno CF, Giancola ML, et al. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis 2005; 41: 1787-93.
6. Best BM, Goicoechea M, Witt MD, et al. A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients. J Acquir Immune Defic Syndr 2007; 46: 433-42.
7. Kappelhoff BS, van Leth F, MacGregor TR, et al. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther 2005; 10: 145-55.
8. Parkin NT, Hellmann NS, Whitcomb JM, et al. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48: 437-43.
9. Sustiva (efavirenz) Capsules and Tablets Prescribing Information. Princeton, NJ: Bristol-Myers Squibb Company, 2009.